Hep C biotech Kadmon files for a $115 million IPO

Kadmon Holdings, a biotech developing therapies for Hepatitis C and other diseases, filed on Friday with the SEC to raise up to $115 million in an initial public offering.

The New York, NY-based company was founded in 2009 and booked $38 million in sales for the 12 months ended March 31, 2016. It plans to list on the NYSE under the symbol KDMN. Kadmon filed confidentially on February 8, 2016. Citi and Jefferies are the joint book runners on the deal. No pricing terms were disclosed. Renaissance Capital - manager of IPO-focused ETFs

Share on Google Plus

About Jessica Hornberger

This is a short description in the author block about the author. You edit it by entering text in the "Biographical Info" field in the user admin panel.